PeterLabs Holdings Bhd (0171) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of PeterLabs Holdings Bhd MYR 0.22, price MYR 0.22, upside +0.0%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PeterLabs Holdings Bhd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 0.1618 MYR – 0.4500 MYR · fair‑value band 0.1500 MYR – 0.2900 MYR · the 0.2200 MYR price screens below the 0.2200 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow PeterLabs Holdings Bhd in your weekly email
Every Wednesday you see whether PeterLabs Holdings Bhd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PeterLabs Holdings Berhad, an investment holding company, engages in manufacturing, distribution, trading, and export of animal health and nutrition products in Malaysia and internationally. The company operates through three segments: Manufacturing, Trading, and Others.
Show more
PeterLabs Holdings Berhad, an investment holding company, engages in manufacturing, distribution, trading, and export of animal health and nutrition products in Malaysia and internationally. The company operates through three segments: Manufacturing, Trading, and Others. It offers biosecurity products and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements. The company also engages in the distribution of consumer goods, including home care, oral care, baby care, and feminine care products, as well as grain products, and processed foods and beverage products to retailers, such as supermarkets, mini markets, sundry shops, convenience stores, pharmacies, petrol kiosks, Chinese medical halls, and hardware stores. The company was founded in 2002 and is headquartered in Nilai, Malaysia.
Stock analysis
PeterLabs Holdings Bhd (0171) currently trades at 0.2200 MYR, while our model-based Fair Value estimate is 0.2200 MYR, implying the stock looks roughly 0.0% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 0.3100 MYR per share, and 12 of the 24 models we run sit above the 0.2200 MYR price.
Bear case: the Dividend Discount group reads lowest at 0.0600 MYR, and 12 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.1500 MYR (bear) to 0.2900 MYR (bull), the price of 0.2200 MYR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
PeterLabs Holdings Bhd reported revenue of 242M MYR in FY2024 versus 80.0M MYR in FY2020, a compound +31.9%/yr. Reported net income was 2.3M MYR in FY2024, compounding −12.4%/yr from FY2020.
Key figures
Market cap 60.5M MYR (≈ $14.9M) · P/E ratio 22.0 · P/S ratio 0.21 · EPS (TTM) 0.0100 MYR · Dividend yield 1.7% · Net margin 0.9% · Return on equity 225% · Return on assets (EBIT) 5.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 0%, 0171 screens cheaper than that median.
Fair Value models
Bear 0.1500 MYRFair Value 0.2200 MYRBull 0.2900 MYR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then (0.0100 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+30.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.3%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−9.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−11.3%
Dividend (yield on the price)1.7%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 2%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about +20.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Top 25%
Fair Value upside+0% · Above median
Profitability
Return on equity (TTM)225% · Top 25%
Return on assets2% · Below median
Net margin (TTM)0% · Below median
Operating margin (TTM)−2% · Bottom 25%
Growth and dividend
Revenue growth−12% · Bottom 25%
Dividend yield (TTM)1.7% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "PeterLabs Holdings Bhd Fair Value". https://www.fairvalue-calculator.com/stock/0171
Frequently asked questions
Is PeterLabs Holdings Bhd (0171) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.2200 MYR versus a price of 0.2200 MYR, about +0% upside (fairly valued).
What is the fair value of 0171?
Our model-based fair value for PeterLabs Holdings Bhd is 0.2200 MYR (as of Sep 24, 2026), built from audited fundamentals. The current price: 0.2200 MYR.
What is the quality score of 0171?
PeterLabs Holdings Bhd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PeterLabs Holdings Bhd (0171)?
Our model-based price target is the fair value of 0.2200 MYR (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 0.1500 MYR, optimistic scenario 0.2900 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the PeterLabs Holdings Bhd stock forecast for 2026?
Our models put fair value at 0.2200 MYR, about +0% upside versus a price of 0.2200 MYR (fairly valued). Cautious scenario 0.1500 MYR, optimistic scenario 0.2900 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of PeterLabs Holdings Bhd (0171)?
PeterLabs Holdings Bhd reported trailing-twelve-month revenue of about 132M MYR (latest available figure, as of Sep 24, 2026).
Does PeterLabs Holdings Bhd pay a dividend?
PeterLabs Holdings Bhd currently shows a dividend yield of about 1.74% relative to its recent price (as of Sep 24, 2026).
What growth is priced into PeterLabs Holdings Bhd (0171)?
For today's price to be fair in a discounted-cash-flow model, PeterLabs Holdings Bhd would have to grow free cash flow by +22.3 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +20.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0171 use?
Our models discount PeterLabs Holdings Bhd at 9.7 %: a base by market capitalisation (nano), damped by beta 0.34, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PeterLabs Holdings Bhd that is +22.3 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has PeterLabs Holdings Bhd (0171) delivered so far?
Over the past 5 years revenue at PeterLabs Holdings Bhd grew +20.3 % a year. The price currently implies +22.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PeterLabs Holdings Bhd (0171) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into PeterLabs Holdings Bhd (+22.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PeterLabs Holdings Bhd (0171)?
The free-cash-flow yield on the price is 2.79 %: that much free cash flow PeterLabs Holdings Bhd produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PeterLabs Holdings Bhd (0171)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PeterLabs Holdings Bhd it is 0.2200 MYR per share (as of Sep 24, 2026), against a price of 0.2200 MYR. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is PeterLabs Holdings Bhd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0171 trades below its calculated fair value: price 0.2200 MYR, fair value 0.2200 MYR, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0171?
No. The price is what the market pays today (0.2200 MYR); the fair value is what the company's own numbers justify (0.2200 MYR). For PeterLabs Holdings Bhd the two are 0.0000 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is PeterLabs Holdings Bhd worth?
The market values PeterLabs Holdings Bhd at about 60.5M MYR (market capitalisation, as of Sep 24, 2026). Per share that is 0.2200 MYR; our models calculate a fair value of 0.2200 MYR per share.
What do the bullish and bearish scenarios say about 0171?
Our models span a range for PeterLabs Holdings Bhd: cautious scenario 0.1500 MYR, base 0.2200 MYR, optimistic 0.2900 MYR per share (as of Sep 24, 2026, price 0.2200 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0171?
PeterLabs Holdings Bhd trades at a price-to-earnings ratio of 22.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.2200 MYR is built from several models across several years. Other multiples: P/B 0.2, P/S 0.1, EV/EBITDA 1.9.
How solid is the balance sheet of PeterLabs Holdings Bhd (0171)?
Balance-sheet figures for PeterLabs Holdings Bhd (as of Sep 24, 2026): return on equity 224.9%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 0171 from its 52-week high?
PeterLabs Holdings Bhd trades at 0.2200 MYR, about 20% below its 52-week high of 0.2750 MYR and 13% above the low of 0.1950 MYR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2200 MYR is for.
Which stocks are comparable to PeterLabs Holdings Bhd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PeterLabs Holdings Bhd stock attractive at the current price?
The data as of Sep 24, 2026: price 0.2200 MYR, calculated fair value 0.2200 MYR (+0%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0171 calculated?
We run PeterLabs Holdings Bhd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.2200 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. PeterLabs Holdings Bhd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PeterLabs Holdings Bhd (0171)?
The closing price on Sep 24, 2026 was 0.2200 MYR. Our model-based fair value is 0.2200 MYR, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PeterLabs Holdings Bhd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (0.1500 MYR to 0.2900 MYR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of PeterLabs Holdings Bhd
How large is the market capitalisation of PeterLabs Holdings Bhd (0171)?
The market capitalisation of PeterLabs Holdings Bhd is 60.5M MYR (≈ $14.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PeterLabs Holdings Bhd (0171)?
The price-to-sales ratio of PeterLabs Holdings Bhd is 0.21 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PeterLabs Holdings Bhd (0171)?
Earnings per share at PeterLabs Holdings Bhd are 0.0100 MYR (price ÷ EPS = P/E 22.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of PeterLabs Holdings Bhd (0171)?
The dividend yield of PeterLabs Holdings Bhd is 1.7% (payout 38.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PeterLabs Holdings Bhd (0171)?
The net margin of PeterLabs Holdings Bhd is 0.9% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PeterLabs Holdings Bhd (0171)?
The return on equity (ROE) of PeterLabs Holdings Bhd is 225% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PeterLabs Holdings Bhd (0171)?
On an EBIT basis the return on assets of PeterLabs Holdings Bhd is 5.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PeterLabs Holdings Bhd (0171)?
The operating margin of PeterLabs Holdings Bhd is −2.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PeterLabs Holdings Bhd (0171)?
Revenue at PeterLabs Holdings Bhd is growing −11.5% versus a year earlier (3y avg +9.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PeterLabs Holdings Bhd (0171)?
Earnings per share at PeterLabs Holdings Bhd are growing +117% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does PeterLabs Holdings Bhd (0171) carry?
The net debt of PeterLabs Holdings Bhd is 3.3M MYR (fiscal year 2024, ≈ 2.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch PeterLabs Holdings Bhd in the live analysis
One click puts PeterLabs Holdings Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
